The objective of the study was to achieve limb salvage in patients with locally advanced soft tissue sarcomas that can only be treated by amputation or functionally mutilating surgery by performing an isolated limb perfusion (ILP) with tumor necrosis factor (TNF) + melphalan (M) as induction biochemotherapy to obtain local control and make limb-sparing surgery possible.
Objective
The objective of the study was to achieve limb salvage in patients with locally advanced soft tissue sarcomas that can only be treated by amputation or functionally mutilating surgery by performing an isolated limb perfusion (ILP) with tumor necrosis factor (TNF) + melphalan (M) as induction biochemotherapy to obtain local control and make limb-sparing surgery possible.
Summary Background Data
To increase the number of limb-sparing resections in the treatment of locally advanced extremity soft tissue sarcoma, preoperative radiation therapy or chemotherapy or a combination of the two often are applied. The ILP with cytostatic agents alone is another option but rarely is used because of rather poor results. The efficacy of the application of TNF in ILP markedly has changed this situation.
Methods
In 8 cancer centers, 186 patients were treated over a period of almost 4.5 years. There were 107 (57%) primary and 79 (43%) recurrent sarcomas, mostly high grade (1 10 grade III; 51 grade 11; and 25 very large, recurrent, or multiple grade sarcomas). The composition 756 of this series of patients is unusual: 42 patients (23%) had multifocal primary or multiple recurrent tumors; median tumor size was very large (16 cm); 25 patients (13%) had known systemic metastases at the time of the ILP. Patients underwent a 90-minute ILP at 39 to 40 C with TNF + melphalan. The first 55 patients also received interferon-r. A delayed marginal resection of the tumor remnant was done 2 to 4 months after ILP.
Results
A major tumor response was seen in 82% of the patients rendering these large sarcomas resectable in most cases. Clinical response rates were: 33 complete response (CR) (18%), 106 partial response (PR) (57%), 42 no change (NC) (22%), and 5 progressive disease (PD) (3%). Final outcome was defined by clinical and pathologic response: 54 CR (29%), 99 PR (53%), 29 NC (16%), and 4 PD (2%). At a median follow-up of almost 2 years (22 months; range, 6-58 months), limb salvage was achieved in 82%. Regional toxicity was limited and systemic toxicity minimal to moderate, easily managed, with no toxic deaths.
Conclusions
In the setting of isolated limb perfusion, TNF is an active anticancer drug in patients. The ILP with TNF + melphalan can be performed safely in many centers and is an effective induction treatment with a high response rate that can achieve limb salvage in patients with locally advanced extremity soft tissue sarcoma.
Management of locally advanced extremity soft tissue sarcomas (STSs) that leads to an increase in preservation of functional limbs continues to be a challenge. Although control and prevention of distant metastases is a major concern, limb salvage has become all the more 
Leakage Monitoring
During limb perfusion, there was a dynamic balance between two pressure compartments, the systemic vasculature and the isolated circuit, which could be influenced by adjusting the systemic blood pressure or the extracorporeal flow rate or both. Throughout the perfusion period, any potential leakage of the drugs was monitored using a radioactive tracer. A small calibration dose of human serum albumin radiolabelled with 1311 or 99mTc was injected into the systemic circulation and a (tenfold) higher dose of the same isotope into the isolated extremity. Continuous monitoring was performed with a precordial scintillation probe. Systemic leakage was expressed quantitatively as a percentage (100% leakage representing a homogeneous distribution of the isotope in the body). 26 
Cardiopulmonary and Hemodynamic Monitoring
Perioperative monitoring consisted in the early phase of the study of electrocardiogram, urine output, blood pressure, venous and pulmonary pressures, and arterial wedge pressures. This was later only done in high-risk patients. Similarly, the routine administration of low-dose dopamine perioperatively was abandoned. Fluid loading was applied during the operation before releasing the tourniquet after completion of the washout of the limb. 
Marginal Resection of the Tumor Remnant
Resections of the tumor remnants were performed between 4 and 24 weeks after ILP (average of 10 weeks). Usually this period allowed for enough shrinkage of the tumor to become mobile or shrink for more than 50%. The least of margins usually was not more than 1 
RESULTS Tumor Response and Limb Salvage
A major tumor response was seen in 82% of the patients, rendering most of these large sarcomas resectable. The key parameters defining outcome of treatment, clini- 
Repeat Perfusions
Nine patients underwent two perfusions, scheduled 6 to 10 weeks from each other to convert a PR (or NC) into a better response. In six patients, a PR was converted into an CR; in two patients, a PR into a better PR, and in one patient, NC remained NC. Four patients had a second limb perfusion for a local recurrence 12 to 18 months after the first ILP + resection. One patient with >100 tumors in her left forearm, wrist, and hand underwent three perfusions at intervals of 1.0 to 1.5 years because of locally recurrent disease after a CR and longlasting PR.
Amputations
In 34 patients (18%), the limb had to be amputated. Four patients underwent an amputation despite having a histologically confirmed CR. One patient had to be amputated early because of necrosis of a previously heavily irradiated foot and another because tumor involvement of the lower leg was so extensive that after resection of all the necrosis, there was no tissue left to have a viable lower leg. There were two late amputations: in one patient in whom after delayed resection of a 100% necrotic tumor mass developed osteomyelitis because of a period of inadequate soft tissue coverage of the bone ending in a pathologic fracture 17 months after ILP; the second patient underwent an amputation 21 months after ILP despite a CR but due to recurrent ulceration and erysipelas after adjuvant irradiation. All other amputations were done because of insufficient response to the ILP or because of local tumor recurrence 4 to 24 months after ILP.
Systemic Metastasis and Survival
In 25 patients (13%), synchronous metastases were present at the time of ILP; limb salvage was achieved in 23 patients (92%) and 20 patients (80%) have died (median, 9 months); at a median follow-up of almost 2 years, metachronous distant metastases appeared after ILP in 58 (36%) of 161 patients; 44 (27%) of these 58 patients have died (44/58 = 76%).
Regional Toxicity
Regional toxicity was scored according to Wieberdink et al. 28 and found to be moderate. Almost all patients (171 patients) had a perfusion reaction grade II and III. This is similar to the toxicity observed after ILP with melphalan alone. Grade IV toxicity developed in 14 patients. In one patient, grade V toxicity required amputation of an irradiated foot. Transient paraesthesia (fingertips, toes) occurred in 20% of the patients. Transient motor neurapraxia of less than 6 months was observed in 8% and long-lasting motor-neurapraxia (mostly peroneal nerve) was observed in 3%.
Systemic Toxicity
Systemic toxicity was moderate and easily manageable. Almost all patients had fever, sometimes with chills, within 4 hours of the ILP, treated effectively with paracetamol or indomethacin. The following events were reviewed and did not require therapeutic interventions: 
DISCUSSION
This report on our multicentric experience with TNFbased isolated limb perfusions in the management of locally advanced extremity STS in 186 patients represents by far the largest experience in the world.
The 29% CR rate, 53% PR rate, and the 82% limb salvage rate at a median follow-up of almost 2 years in this group of patients with unusually advanced disease (median size, 16 cm; multiple tumors in 23%) show the efficacy of this two-step approach to achieve limb salvage.
It is hard to find comparable series of patients with comparably advanced tumors. Krementz The local recurrence rate of 11% in 126 patients with a single tumor and a delayed resection is low considering the following: large median tumor size, the percentage of recurrent sarcomas treated, and the conservative surgical procedures, followed only in 21% of the patients by additional radiation therapy. These patients had microscopically irradical resections. Because of the size of the irradiation field and/or the involvement of knee or elbow joints, irradiation in many patients was not added to the perfusion and delayed resections for the fear of inflicting too much local toxicity and functional damage. Local recurrence rates probably can be further improved by giving postresection radiation therapy in a higher percentage of cases. In addition to histopathologic examinations, new techniques such as magnetic resonance spectroscopy and positron emission tomography scanning may be quite useful to assess the extent of necrosis and predict the quality of the response and, thus, influence clinical decision making regarding type and timing of the resection of the tumor as well as the decision to add radiation therapy.31 '32 Recurrence rates were high in the 60 patients who did not undergo a delayed resection for reasons such as multiple tumors, pre-existing metastases, and metachronous metastasis, but local control in most cases was sufficient to be overtaken by rapid progression of systemic disease.
Our experience further shows that the procedure is safe and is associated with only little-to-moderate regional and systemic toxicity. Systemic toxicity is related to the leakage rate during the perfusion, and continuous leakage monitoring, as described, is mandatory to perfuse safely and be able to take corrective measures during the perfusion.3334 Toxicity can be further reduced by prolonging the washout procedure at the end of the ILP. 35 The shown recently by the Rotterdam perfusion group that both melphalan and TNF are crucial to obtain antitumor effects, each agent alone being ineffective.
In contrast to the disappointing results of the systemic administration of TNF in humans in phase I and II trials,43-45 TNF may be applied successfully in humans in a setting where the tumor and tumor vascular bed can be exposed to very high concentrations. Apart from direct antitumor effects,4647 TNF also has in humans mainly important indirect (vascular) antitumor effects such as thrombocyte aggregation, erythrostasis, endothelial, and vascular destruction as have been described by us. [48] [49] [50] These observations resemble many of the phenomena reported in experimental tumor systems.51'52 These selective vasodestructive effects on tumor vessels can be shown elegantly by pre-and post-ILP angiographies.53 Neutrophils also may play an important role in the antitumor effects as extravasation and invasion of the tumor by neutrophils can be observed after ILP with TNF-a. 48 Observations in the sarcoma perfusion model in rats in our laboratory suggest strongly that both neutrophils and platelets play a crucial role as much of the TNF antitumor effect is lost in rats with severe radiation-induced neutropenia. 54 The evidence that the common denominator, that is, the tumor vascular bed, is the target for TNF would predict that any histologic type of solid tumor is prone to be sensitive to the effects of TNF. This is exactly our experience as we have observed tumor responses in 20 types of sarcomas, melanomas, as well as in a range of other tumors in extremities (unpublished observations, 1991-1996) . Thus, TNF eventually may be used successfully in a number of settings such as isolated lung,55 liver,56'57 or kidney58 perfusions in the treatment of a variety of tumors.
CONCLUSIONS
The ILP with TNF + melphalan is a new option in the management of locally advanced and irresectable soft tissue sarcomas of the extremities. The procedure is safe and is associated with a high response rate and a high limb salvage rate. It merits further evaluation in an increasing number of centers that deal with the treatment of soft tissue sarcomas to further define its value and place in the management of extremity tumors.
